Human medicinehttps://www.ema.europa.eu/en/homepageHuman medicineen-gbCopyright: (C) European Medicines AgencySun, 30 Jun 2024 13:28:11 +0200Tue, 26 Mar 2024 14:40:00 +0100Human medicines European public assessment report (EPAR): Rystiggo, Rozanolixizumab, Date of authorisation: 05/01/2024, Revision: 1, Status: Authorisedhttps://www.ema.europa.eu/en/medicines/human/EPAR/rystiggoHuman medicines European public assessment report (EPAR): Rystiggo, Rozanolixizumab, Date of authorisation: 05/01/2024, Revision: 1, Status: Authorisedhttps://www.ema.europa.eu/en/medicines/human/EPAR/rystiggoTue, 26 Mar 2024 14:40:00 +0100Human medicineRystiggo : EPAR - Product informationhttps://www.ema.europa.eu/system/files/documents/product-information/ema-combined-h-5824-en_1.pdfRystiggo : EPAR - Product informationhttps://www.ema.europa.eu/system/files/documents/product-information/ema-combined-h-5824-en_1.pdfTue, 26 Mar 2024 12:24:00 +0100Human medicine